SECsense Logo

Aquestive Therapeutics 8-K Report: Key Insights & Updates on December 19, 2024

$AQST
Form 8-K
Filed on: 2024-12-19
Source
Aquestive Therapeutics 8-K Report: Key Insights & Updates on December 19, 2024

Here are the key insights extracted from the provided financial report section:

  1. Entity Information:
  • Company Name: Aquestive Therapeutics, Inc.
  • CIK: 0001398733
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-38599
  • EIN: 82-3827296
  1. Contact Information:
  • Address: 30 Technology Drive, Warren, NJ 07059
  • Phone Number: 908-941-1900
  1. Report Type:
  • Filing Type: 8-K (Current Report)
  • Filing Date: December 19, 2024
  1. Stock Information:
  • Common Stock: Par value of $0.001 per share
  • Ticker Symbol: AQST
  • Exchange: NASDAQ
  1. Period Covered:
  • Report Period: The report covers a single day, December 19, 2024, indicating it may contain significant events or changes occurring on that date.

Insights:

  • The 8-K filing suggests that Aquestive Therapeutics may have had an important event or announcement on December 19, 2024, which required disclosure to the SEC.
  • As a publicly traded company on NASDAQ, the information in the 8-K is critical for investors and stakeholders to assess any significant changes in the company's operations, financial conditions, or other events that might impact stock performance.
  • The inclusion of the CIK and SEC file number provides a way to track and verify this filing within the SEC's database.

This information is essential for stakeholders to understand the company's status and any potential implications for investment or operational strategies.